Thousand Oaks-based Amgen said Friday afternoon that it has resolved a patent litigation suite with Teva. The firm said that the United States District Court in Pennsylvania has issued a final judgement and permanent injunction against Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, prohibiting them from infringing on its patents for human g-CSF. Amgen said the deal will hold off production of Teva's products until November 10, 2013.